Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in asbestosis safety and tolerability study
NL-OMON47764Phase 2Active, not recruiting
- Sponsor
- NVALT
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in asbestosis, sponsored by NVALT. Primary endpoint: Safety and tolerability. Started Apr 2019; status: active, not recruiting.
02
Drugs
pirfenidone
03
Conditions
asbestosis
Beyond the preview
Go deeper on NL-OMON47764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47764.